Myeloma | Multiple Myeloma CME Learning Center

Multiple Myeloma
CME Learning Center

CME Activities

FDA Safety Changes: Lenalidomide Increases Risk for Second Cancers CME The US Food and Drug Administration has updated its safety review regarding the risk for second primary cancers in patients with newly diagnosed multiple myeloma treated with lenalidomide.
Medscape Education Clinical Briefs, May 2012
Special Report – Year 2: Improving Conditioning for Hematopoietic Stem Cell Transplantation CME/CE Experts review studies and new guidelines on HSCT presented at the 2012 BMT Tandem Meetings.
Medscape Education Oncology, April 2012
B-Cell Malignancies: Updates on Current and Emerging Treatment Strategies -- Issue 8 CME Experts discuss recent advances in MM, CLL, and NHL.
Medscape Education Oncology, April 2012
The Challenge of Relapsed and/or Refractory Multiple Myeloma CME Dr David Roodman reviews and discusses current and emerging treatment approaches for patients with relapsed and/or refractory multiple myeloma.
Medscape Education Oncology, March 2012
Updates on Hematologic Malignancies From the 2011 ASH Meeting Faculty reviews and discusses the exciting data on AML/MDS, CML, lymphoma, and myeloma presented at the 53rd annual ASH meeting.
Medscape Education Oncology, March 2012
Treatment of Patients With Relapsed or Refractory Multiple Myeloma: Current and Emerging Options CME Watch Drs Lonial, Jakubowiak, Niesvizky, and Vij discuss exciting new data from the 2011 ASH meeting on relapsed and refractory myeloma.
Medscape Education Oncology, February 2012
B-Cell Malignancies: Updates on Current and Emerging Treatment Strategies -- Issue 7 CME Experts discuss the data presented at ASH 2011 in MM, CLL, and NHL.
Medscape Education Oncology, February 2012
Focus on Multiple Myeloma: Updates From the 2011 ASH Meeting CME Watch and read about the exciting new data recently presented at the 2011 ASH Meeting focusing on multiple myeloma.
Medscape Education Oncology, February 2012
Clinical Conversations: Nursing Care for Patients With Multiple Myeloma CE Page Bertolotti and Kena Miller discuss treatment implications for nurses caring for patients with multiple myeloma.
Medscape Education Oncology, February 2012
Management of Myeloma-Associated Renal Dysfunction in the Era of Novel Therapies CME How should multiple myeloma be treated in the setting of renal impairment? The current review explores this question.
Expert Review of Hematology, February 2012
Multiple Myeloma: The Pharmacist’s Perspective CE Listen to Dr Donald Harvey discuss the roles the oncology pharmacist has in the overall management of the patients with multiple myeloma.
Medscape Education Oncology, January 2012
Aspirin or Enoxaparin Thromboprophylaxis for Patients With MM Treated With Lenalidomide CME Aspirin may be as effective and less expensive than low-molecular-weight heparin as thromboprophylaxis in low-risk, newly diagnosed patients treated with lenalidomide for multiple myeloma.
Blood, January 2012
Maintaining Bone Health in Patients With Breast Cancer, Prostate Cancer, and Multiple Myeloma CME/CE Experts address the challenges of preventing bone-related complications in 3 different clinical scenarios.
Medscape Education Oncology, January 2012
Maintaining Bone Health in Cancer: An Expert Column Series for Pharmacists CE What are the specific risks in breast cancer, prostate cancer, and multiple myeloma?
Medscape Education Oncology, January 2012
Maintaining Bone Health in Cancer: An Expert Column Series CME/CE What are the implications in breast cancer, prostate cancer, and multiple myeloma?
Medscape Education Oncology, December 2011
Expert Highlights on Relapsed/Refractory Multiple Myeloma From 2011 ASH CME Drs. Anderson and Roodman discuss the exciting new data on relapsed/refractory multiple myeloma recently presented at the 2011 ASH meeting.
Medscape Education Oncology, December 2011
Newly Diagnosed Multiple Myeloma: Induction Treatment Before Autologous Stem Cell Transplantation CME Reduced doses of vtD are effective as induction in patients with multiple myeloma, with a lower incidence of peripheral neuropathy than with higher-dose VD.
Blood, November 2011
Addressing Disparities in the Treatment of Patients With Newly Diagnosed Multiple Myeloma CME Drs. Richardson, Bensinger, Lonial, and Krikorian discuss disparities in the treatment of patients with newly diagnosed multiple myeloma.
Medscape Education Oncology, November 2011
The Impact of Genomics on the Management of Myeloma CME Genomics has an increasingly important role in the management of patients with multiple myeloma. The current review describes this emerging field.
JNCCN - Journal of the National Comprehensive Cancer Network, October 2011
Treatment of Patients With Newly Diagnosed Multiple Myeloma CME In 2 clinical cases, Dr. G. David Roodman examines the variety of treatment strategies available for patients newly diagnosed with multiple myeloma.
Medscape Education Oncology, September 2011

FDA Safety Changes: Lenalidomide Increases Risk for Second Cancers CME
May 2012
Patients With Multiple Myeloma and Renal Impairment: Frontline Treatment CME
July 2011
Bisphosphonates Are Essential Component of Multiple Myeloma Treatment
September 2009
FDA Safety Changes: Toprol XL, Revlimid, Fludara
April 2009
Management of Multiple Myeloma Reviewed
October 2008

About Multiple Myeloma

Multiple myeloma is a rare cancer characterized by a proliferation of malignant plasma cells. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. Multiple myeloma is more commonly diagnosed in persons over 65 years of age, in men than in women, and in blacks than in whites. Early diagnosis is difficult because symptoms may not appear until the cancer is advanced. The average 5-year survival rate is about 30%. Despite recent therapeutic advances that have improved the quality of life and length of survival, multiple myeloma is incurable at present. In addition to drugs that inhibit the destruction of bone, conventional treatment for multiple myeloma involves chemotherapy and corticosteroids. Bone marrow transplantation also may be beneficial. Newer treatment approaches include immunomodulating therapies and targeted agents. Ongoing research in the field aims to elucidate the etiology of multiple myeloma and develop more effective treatments.

Multiple MyelomaCME Learning Center

CME Activities

Latest Clinical Briefs in Multiple Myeloma

About Multiple Myeloma

Multiple Myeloma
CME Learning Center